ALS ONE Research Symposium – Presentation by Peter Vanderklish, PhD of Spinogenix

Spinogenix Lands $4M in New Federal Grants

Spinogenix awarded $1M to advance clinical testing of SPG302

Spinogenix: World-first trial giving hope to those living with MND

Clinical trial of oral ALS therapy SPG302 is enrolling in Australia | ALS News Today

Human Trial Gives Hope to MND Patients

Australians with MND will be the first in the world to trial a new drug

World first drug trial for MND treatment | Sky News Australia

A world-first trial for a new drug that may slow the progression of motor neurone disease is set to begin in Melbourne.

World first drug trial for MND treatment | The Australian
